- Home
- SAIH vs NEUP Comparison
SAIH vs NEUP Comparison
Compare SAIH & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- NEUP
- Stock Information
- Founded
- SAIH 2019
- NEUP 1996
- Country
- SAIH Singapore
- NEUP United States
- Employees
- SAIH N/A
- NEUP N/A
- Industry
- SAIH
- NEUP
- Sector
- SAIH
- NEUP
- Exchange
- SAIH NYSE
- NEUP Nasdaq
- Market Cap
- SAIH 12.3M
- NEUP 12.7M
- IPO Year
- SAIH N/A
- NEUP N/A
- Fundamental
- Price
- SAIH $7.20
- NEUP $7.01
- Analyst Decision
- SAIH
- NEUP Strong Buy
- Analyst Count
- SAIH 0
- NEUP 1
- Target Price
- SAIH N/A
- NEUP $21.00
- AVG Volume (30 Days)
- SAIH 20.2K
- NEUP 22.3K
- Earning Date
- SAIH 04-28-2025
- NEUP 08-15-2025
- Dividend Yield
- SAIH N/A
- NEUP N/A
- EPS Growth
- SAIH N/A
- NEUP N/A
- EPS
- SAIH N/A
- NEUP 0.00
- Revenue
- SAIH $5,543,000.00
- NEUP $15,662,715.00
- Revenue This Year
- SAIH N/A
- NEUP N/A
- Revenue Next Year
- SAIH N/A
- NEUP N/A
- P/E Ratio
- SAIH N/A
- NEUP $4,149.50
- Revenue Growth
- SAIH N/A
- NEUP N/A
- 52 Week Low
- SAIH $3.00
- NEUP $2.90
- 52 Week High
- SAIH $26.98
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- NEUP N/A
- Support Level
- SAIH N/A
- NEUP N/A
- Resistance Level
- SAIH N/A
- NEUP N/A
- Average True Range (ATR)
- SAIH 0.00
- NEUP 0.00
- MACD
- SAIH 0.00
- NEUP 0.00
- Stochastic Oscillator
- SAIH 0.00
- NEUP 0.00
About SAIH SAIHEAT LIMITED
Saiheat Ltd develops technologies for the Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations. The Company has four reportable segments: equipment sales, hosting, mining pool business, and mining.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.